OTSUKA PHARMACEUTICAL DEVELOPMENT & COMMERCIALIZATION, INC.
A Clinical Trial to Study the Efficacy and Safety of an Investigational Drug in Acutely Psychotic People With Schizophrenia
- Conditions
- Schizophrenia
- Interventions
- First Posted Date
- 2019-08-28
- Last Posted Date
- 2024-06-26
- Target Recruit Count
- 463
- Registration Number
- NCT04072354
- Locations
- 🇺🇸
Woodland International Research Group, LLC, Little Rock, Arkansas, United States
🇺🇸Advanced Research Center, Inc., Anaheim, California, United States
🇺🇸CITrials, Bellflower, California, United States
A Clinical Study to Investigate the Effect of an Investigational Drug as an Added Medication to an Antipsychotic, in Adults With Schizophrenia, as Measured Positron Emission Tomography (PET) Imaging
- First Posted Date
- 2019-07-31
- Last Posted Date
- 2024-12-27
- Target Recruit Count
- 22
- Registration Number
- NCT04038957
- Locations
- 🇬🇧
Research Site, London, United Kingdom
A Trial of Multiple-doses of Aripiprazole in Adults With Schizophrenia or Bipolar 1 Disorder
- First Posted Date
- 2019-07-23
- Last Posted Date
- 2023-11-18
- Target Recruit Count
- 266
- Registration Number
- NCT04030143
- Locations
- 🇺🇸
Woodland International Research Group, Rogers, Arkansas, United States
🇺🇸CITrials - Bellflower, Bellflower, California, United States
🇺🇸Collaborative Neuroscience Network, Garden Grove, California, United States
Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Negative Symptoms of Schizophrenia
- First Posted Date
- 2019-04-01
- Last Posted Date
- 2024-05-24
- Target Recruit Count
- 136
- Registration Number
- NCT03896945
- Locations
- 🇵🇱
Clinical Research Site, Tuszyn, Woj.Iodzkie, Poland
🇺🇸Clinical Research Site #840-041, Anaheim, California, United States
🇺🇸Clinical Research Site #840-013, Bellflower, California, United States
A Trial in Adult Participants With Schizophrenia Treated Prospectively for 6-months With Abilify MyCite®
- Conditions
- Schizophrenia
- First Posted Date
- 2019-03-27
- Last Posted Date
- 2021-09-05
- Target Recruit Count
- 277
- Registration Number
- NCT03892889
- Locations
- 🇺🇸
Alea Research, Phoenix, Arizona, United States
🇺🇸Woodland International Research Group, Little Rock, Arkansas, United States
🇺🇸ADVANCED RESEARCH CENTER, Inc., Anaheim, California, United States
Trial to Assess the Bioavailability of Quetiapine Versus Seroquel® in Subjects With Schizophrenia or Bipolar Disorder
- Conditions
- Bipolar DisorderSchizophrenia
- Interventions
- First Posted Date
- 2019-03-13
- Last Posted Date
- 2020-09-02
- Target Recruit Count
- 58
- Registration Number
- NCT03872596
- Locations
- 🇺🇸
Collaborative Neurosciences Network, LLC, Long Beach, California, United States
A Trial of Single- and Multiple-doses of Aripiprazole in Adult Subjects With Schizophrenia or Bipolar I Disorder
- First Posted Date
- 2019-02-26
- Last Posted Date
- 2020-09-02
- Target Recruit Count
- 72
- Registration Number
- NCT03854409
- Locations
- 🇺🇸
Woodland International Research Group, Little Rock, Arkansas, United States
🇺🇸Collaborative Neuroscience Network, Garden Grove, California, United States
🇺🇸Hassman Research Institute, Berlin, New Jersey, United States
Efficacy and Safety of Oral OPS-2071 in Participants With Crohn's Disease Showing Symptoms of Active Inflammation
- First Posted Date
- 2019-02-21
- Last Posted Date
- 2021-06-15
- Target Recruit Count
- 3
- Registration Number
- NCT03850509
- Locations
- 🇺🇸
United States, California, San Carlos, California, United States
🇺🇸United States, Colorado, Colorado Springs, Colorado, United States
🇺🇸United States, Florida, Plantation, Florida, United States
A Phase 1/2 Trial of Multiple Oral Doses of OPC-167832 for Uncomplicated Pulmonary Tuberculosis
- Conditions
- Pulmonary TB
- Interventions
- Drug: 90 mg OPC-167832Drug: RHEZDrug: 10 mg OPC-167832Drug: 3 mg OPC-167832Drug: 30 mg OPC-167832Drug: 30 mg OPC-167832 + 300 mg delamanid + 400 mg BDQDrug: 30 mg OPC-167832 + 300 mg delamanidDrug: 30 mg OPC-167832 + 400 mg BDQ
- First Posted Date
- 2018-09-20
- Last Posted Date
- 2023-11-18
- Target Recruit Count
- 122
- Registration Number
- NCT03678688
- Locations
- 🇿🇦
University of Cape Town (Pty) Ltd., Cape Town, Mowbray, South Africa
🇿🇦Satellite Site: Task at Brooklyn Chest Hospital, Cape Town, South Africa
🇿🇦TASK Clinical Research Centre, Cape Town, South Africa
Trial to Evaluate the Long-term Efficacy of Oral Aripiprazole in the Treatment of Pediatric Participants With Tourette's Disorder
- First Posted Date
- 2018-09-07
- Last Posted Date
- 2021-03-09
- Target Recruit Count
- 36
- Registration Number
- NCT03661983
- Locations
- 🇺🇸
Advanced Research Center, Anaheim, California, United States
🇺🇸CT Trials - Riverside, Riverside, California, United States
🇺🇸Syrentis Clinical Research, Santa Ana, California, United States